Hi all,
Here is a quite difficult abstract about prediction of the responsiveness to azacitidine in high-risk MDS.
The important info is that the researcher soner or later will be able to know which patients that could be treated with Vidaza. We know that more than 50% will respond but the other patients only loose time and should try other drugs.
http://www.pnas.org/content/early/20...09106.abstract
Kind regards
birgitta-A